Affiliation:
1. Department of Pharmacy, Amity Institute of Pharmacy, Amity University, Lucknow Campus, U.P., 226010, India
Abstract
Abstract:
Cardiovascular diseases (CVDs), which stand as the primary contributors to illness and
death on a global scale, include vital risk factors like hyperlipidemia, hypertension, diabetes, and
smoking, to name a few. However, conventional cardiovascular risk factors offer only partial insight
into the complexity of CVDs. Lately, a growing body of research has illuminated that the
gut microbiome and its by-products are also of paramount importance in the initiation and progression
of CVDs. The gastrointestinal tract houses trillions of microorganisms, commonly known as
gut microbiota, that metabolize nutrients, yielding substances like trimethylamine-N-oxide (TMAO),
bile acids (BAs), short-chain fatty acids (SCFAs), indoxyl sulfate (IS), and so on. Strategies
aimed at addressing these microbes and their correlated biological pathways have shown
promise in the management and diagnosis of CVDs. This review offers a comprehensive examination
of how the gut microbiota contributes to the pathogenesis of CVDs, particularly atherosclerosis,
hypertension, heart failure (HF), and atrial fibrillation (AF), explores potential underlying
mechanisms, and highlights emerging therapeutic prospects in this dynamic domain.
Publisher
Bentham Science Publishers Ltd.